Miles P Sparrow
Overview
Explore the profile of Miles P Sparrow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abushamma S, Yadete T, Nero N, Falloon K, Parker C, Abreu M, et al.
J Crohns Colitis
. 2025 Mar;
PMID: 40066499
Background And Aims: Over 10% of patients with Crohn's disease require permanent ileostomy. We aimed to summarize the existing data on diagnosis, definitions of recurrence, and management of Crohn's disease...
2.
Karp J, Shen H, Goodwin T, Sparrow M
Case Rep Gastroenterol
. 2025 Feb;
19(1):62-66.
PMID: 39981168
Introduction: Vedolizumab is a commonly prescribed biologic agent due to its safety profile and clinical efficacy. Severe infusion-related reactions are exceedingly rare, with no previously documented cases of anaphylaxis to...
3.
Little R, Jayawardana T, Koentgen S, Zhang F, Connor S, Boussioutas A, et al.
eGastroenterology
. 2025 Feb;
2(1):e100006.
PMID: 39944752
The pathogenesis of inflammatory bowel disease (IBD) is complex and multifactorial. Undertreated disease has substantial individual and societal consequences. Current patient classification and subsequent positioning of IBD therapy are based...
4.
Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future
Cameron K, Nguyen A, Gibson D, Ward M, Sparrow M, Gibson P
J Gastroenterol Hepatol
. 2025 Feb;
PMID: 39894941
Background: Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating...
5.
Honap S, Caron B, Ollech J, Fischman M, Papamichael K, de Jong D, et al.
Dig Dis Sci
. 2025 Jan;
PMID: 39869163
Background: Therapeutic drug monitoring is important for optimizing anti-tumor necrosis factor-α (TNF-α) therapy in inflammatory bowel disease. However, the exposure-response relationship has never been assessed in pouchitis. Aims: To explore...
6.
Swaminathan A, Sparrow M, Gearry R
Aliment Pharmacol Ther
. 2024 Nov;
61(2):408-409.
PMID: 39614419
No abstract available.
7.
Swaminathan A, Sparrow M
World J Gastroenterol
. 2024 Nov;
30(39):4260-4266.
PMID: 39492828
In this editorial we comment on the article by Pacheco published in a recent issue of the . We focus specifically on the burden of illness associated with perianal fistulizing...
8.
Swaminathan A, Day A, Sparrow M, Peyrin-Biroulet L, Siegel C, Gearry R
Aliment Pharmacol Ther
. 2024 Oct;
60(9):1176-1199.
PMID: 39403053
Background: Inflammatory bowel disease (IBD) follows a heterogenous disease course and predicting a patient's prognosis is challenging. There is a wide burden of illness in IBD and existing tools measure...
9.
Leong R, Sakiris A, Arzivian A, Chetwood J, Chaemsupaphan T, Sparrow M, et al.
Aliment Pharmacol Ther
. 2024 Oct;
61(1):132-144.
PMID: 39387155
Background: Given the introduction of new advanced therapies for inflammatory bowel diseases (IBDs), expanded risk mitigation strategies are essential. Aims: To create a comprehensive set of statements on assessment procedures...
10.
Roblin X, Little R, Mathieu N, Paul S, Nancey S, Barrau M, et al.
Expert Rev Gastroenterol Hepatol
. 2024 Oct;
18(10):575-586.
PMID: 39382556
Introduction: Therapeutic Drug Monitoring (TDM) has an important role in the management of inflammatory bowel disease (IBD) patients on infliximab (IFX) or adalimumab and is recommended in IBD patients presenting...